Literature DB >> 29043880

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Mark B Geyer1,2, Shwetha H Manjunath3, Andrew G Evans4, Jae H Park1,2, Marco L Davila5, Corey S Cutler6, Xiuyan Wang2, Yongzeng Wang7, Brigitte Senechal7, Isabelle Rivière2,7, Michel Sadelain2, Jane L Liesveld8, Renier J Brentjens1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29043880      PMCID： PMC6037308          DOI： 10.1080/10428194.2017.1390237

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  16 in total

1.  Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

Authors:  Meir Wetzler; Ben L Sanford; Joanne Kurtzberg; Divino DeOliveira; Stanley R Frankel; Bayard L Powell; Jonathan E Kolitz; Clara D Bloomfield; Richard A Larson
Journal:  Blood       Date:  2007-01-30       Impact factor: 22.113

2.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

3.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

4.  B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia: A Report of Four Cases.

Authors:  Zaher Chakhachiro; C Cameron Yin; Lynne V Abruzzo; Tariq N Aladily; Lynn L Barron; Haley E Banks; Deborah A Thomas; Michael Keating; L Jeffrey Medeiros; Yang O Huh
Journal:  Am J Clin Pathol       Date:  2015-08       Impact factor: 2.493

5.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

6.  PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.

Authors:  Fabienne McClanahan; Bola Hanna; Shaun Miller; Andrew James Clear; Peter Lichter; John G Gribben; Martina Seiffert
Journal:  Blood       Date:  2015-03-23       Impact factor: 22.113

7.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

8.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

10.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113
View more
  2 in total

1.  Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.

Authors:  Xiuyan Wang; Oriana Borquez-Ojeda; Jolanta Stefanski; Fang Du; Jinrong Qu; Jagrutiben Chaudhari; Keyur Thummar; Mingzhu Zhu; Ling-Bo Shen; Melanie Hall; Paridhi Gautam; Yongzeng Wang; Brigitte Sénéchal; Devanjan Sikder; Prasad S Adusumilli; Renier J Brentjens; Kevin Curran; Mark B Geyer; Sham Mailankhody; Roisin O'Cearbhaill; Jae H Park; Craig Sauter; Susan Slovin; Eric L Smith; Isabelle Rivière
Journal:  Mol Ther Methods Clin Dev       Date:  2021-07-16       Impact factor: 5.849

2.  Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  Qiang Zeng; Bing Xiang; Zhigang Liu
Journal:  Cancer Med       Date:  2021-11-11       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.